Risk Factors and Outcomes Associated with Isolation of Meropenem High-Level-Resistant Pseudomonas aeruginosa
- 1 August 2009
- journal article
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 30 (8) , 746-752
- https://doi.org/10.1086/603527
Abstract
Objective.: To determine risk factors and outcomes for patients with meropenem high–level-resistant Pseudomonas aeruginosa (MRPA) (minimum inhibitory concentration [MIC] ≥ 32 μg/mL).Design.: Case-control-control.Setting.: An 867-bed urban, teaching hospital.Patients.: Fifty-eight MRPA case patients identified from an earlier P. aeruginosa study; 125 randomly selected control patients with meropenem-susceptible P. aeruginosa (MSPA) (MIC ≤ 4 μg/mL), and 57 control patients without P. aeruginosa (sampled by case date/location).Methods.: Patient data, outcomes, and costs were obtained via administrative database. Cases were compared to each control group while controlling for time at risk (days between admission and culture, or entire length of stay [LOS] for patients without P. aeruginosa).Results.: A multivariable model predicted risks for MRPA versus MSPA (odds ratio [95% confidence interval]): more admissions (in the prior 12 months) (1.41 [1.15, 1.74]), congestive heart failure (2.19 [1.03, 4.68]), and Foley catheter (2.53 [1.18, 5.45]) (adj. R2 = 0.28). For MRPA versus no P. aeruginosa, risks were age (in 5-year increments) (1.17 [1.03, 1.33]), more prior admissions (1.40 [1.08, 1.81]), and more days in the intensive care unit (1.10 [1.03, 1.18]) (adj. R2 = 0.32). Other invasive devices (including mechanical ventilation) and previous antibiotic use (including carbapenems) were nonsignificant. MRPA mortality (31%) did not differ from that of MSPA (15%) when adjusted for time at risk (P = .15) but did from mortality without P. aeruginosa (9%) (P = .01 ). Median LOS and costs were greater for MRPA patients versus MSPA patients and patients without P. aeruginosa: 30 days versus 16 and 10 (P < .01 ) and $88,425 versus $28,620 and $22,605 (P <.01).Conclusions.: Although antibiotic use has been shown to promote resistance, our data found that prior antibiotic use was not associated with MRPA acquisition. However, admission frequency and Foley catheters were, suggesting that infection control measures are essential to reducing MRPA transmission.Keywords
This publication has 15 references indexed in Scilit:
- Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on MortalityAntimicrobial Agents and Chemotherapy, 2008
- Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modelling: application to meropenem dosage and combination therapyClinical Microbiology & Infection, 2007
- Imipenem Resistance Among Pseudomonas aeruginosa Isolates Risk Factors for Infection and Impact of Resistance on Clinical and Economic OutcomesInfection Control & Hospital Epidemiology, 2006
- Overview of Nosocomial Infections Caused by Gram-Negative BacilliClinical Infectious Diseases, 2005
- Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolatesAPMIS, 2005
- Reference Group Choice and Antibiotic Resistance OutcomesEmerging Infectious Diseases, 2004
- Risk Factors for Imipenem-Resistant Pseudomonas aeruginosa among Hospitalized PatientsClinical Infectious Diseases, 2002
- Resistance Patterns Among Nosocomial PathogensChest, 2001
- Nosocomial infections in medical intensive care units in the United StatesCritical Care Medicine, 1999
- Ventilator-associated Pneumonia Caused by Potentially Drug-resistant BacteriaAmerican Journal of Respiratory and Critical Care Medicine, 1998